# Diabetes Research Hub — Monitor Report
**Run:** 2026-06-20 (automated, scheduled)
**Reviewer:** Hub Monitor (Claude)
**Scope:** Read-only review of latest script outputs + web check. No files modified.

---

## Bottom line (what's actionable)

1. **Two new FDA actions landed since the last manual review and are NOT yet reflected in our trial/tracker notes** — teplizumab pediatric (ages 8–17) Stage 3 T1D indication (FDA, ~Jun 12) and orforglipron (Foundayo) oral GLP-1 approval for chronic weight management. Both touch therapies we explicitly track. **Action: add to tracker + Research_Findings_Summary.**
2. **Clinical-trial layer was flat today** — 0 new, 0 removed, 0 status changes, 0 newly posted results vs. 2026-06-19. Nothing to chase on the trial diff.
3. **Gap analysis is 1 day old (fine), but the source PubMed date range still ends 2026/04/20** — the gap matrix is querying a stale window. **Action: re-run `project1_literature_gap_analysis.py` with date range extended through June.**
4. **One genuinely cross-domain new paper today** worth a look: retatrutide / triple-agonist narrative review in adolescent obesity (PMID 42318576).

---

## File System Status

All four expected script outputs exist and are **fresh (today, 2026-06-20)**:

| File | Last modified | Status |
|------|--------------|--------|
| hub_monitor_report.md | 2026-06-20 07:05 | ✅ current |
| clinical_trials_latest.json | 2026-06-20 07:04 | ✅ current (821 trials) |
| pubmed_recent_latest.json | 2026-06-20 07:05 | ✅ current (173 papers, 30-day lookback) |
| literature_gap_report.md | 2026-06-19 08:09 | ⚠️ 1 day old; **underlying date range ends 2026/04/20** |
| literature_gap_data.json | 2026-04-20 15:35 | ⚠️ **61 days old** — stale |

**hub_monitor.py self-flag:** 728 result files older than 14 days (expected — these are dated snapshot archives, not a problem). One real staleness item: `literature_gap_data.json` (the matrix backing the gap report) has not been regenerated since April 20.

---

## Clinical Trial Changes

**Daily diff (2026-06-19 → 2026-06-20):** New 0 · Removed 0 · Status changes 0 · New results 0. *No trial churn today.*

**Snapshot totals:** 821 unique trials — 263 RECRUITING, 143 NOT_YET_RECRUITING, 300 COMPLETED. 124 are Phase 3; **46 are Phase 3 + RECRUITING**.

**Key Phase 3 trials to keep on the watch list (status as of today):**

| NCT | Sponsor | Focus | Status |
|-----|---------|-------|--------|
| NCT04786262 | Vertex | VX-880 (zimislecel) islet cell therapy, T1D | RECRUITING |
| NCT06832410 | Vertex | VX-880 (zimislecel) additional Phase 3 arm | RECRUITING |
| NCT07222137 | Eli Lilly | Baricitinib to delay Stage 3 T1D | RECRUITING |
| NCT07222332 | Eli Lilly | Baricitinib to preserve beta-cell function | RECRUITING |
| NCT07088068 | Sanofi | Teplizumab combination, Stage 3 delay | RECRUITING |
| NCT07564414 | Novo Nordisk | CagriSema dose comparison | RECRUITING |
| NCT07613307 | Eli Lilly | Orforglipron (LY3502970) | NOT_YET_RECRUITING |
| NCT06334133 | vTv Therapeutics | Cadisegliatin (glucokinase activator) adjunct to insulin | RECRUITING |

Vertex also has NCT05791201 (VX-264 / encapsulated islets) at Phase 1/2, ACTIVE_NOT_RECRUITING. Sana Biotechnology: no trials matched in the current snapshot (worth confirming our query terms capture Sana's hypoimmune programs).

**Recently posted results (since 2026-06-01, 16 trials)** — mostly devices/diet/SGLT2; two worth a glance per our Tier-1 cell-therapy focus:
- **NCT01897688** (2026-06-18) — Phase 3 single-center islet transplantation study, results posted.
- **NCT04776239** (2026-06-16) — Allogeneic MSC infusion therapy, results posted.

None of these are flagged as high-priority breakthroughs; logging for completeness.

---

## PubMed Highlights

30-day lookback: **173 unique papers** across 16 alert domains. Daily diff vs. yesterday: **+34 new, −30 dropped**.

**Cross-domain papers (highest value — appear in ≥2 domains):**

| PMID | Domains | Title (truncated) |
|------|---------|-------------------|
| 42318576 | T2D GLP-1 New + Key Therapy: retatrutide | GLP-1 Agonists in Adolescent Obesity: Single, Dual, Triple Agonists (narrative review) |
| 42269843 | T1D Immunotherapy + teplizumab | Targeting shared immune pathways in MS and T1D |
| 42267680 | T1D Immunotherapy + teplizumab | Early assessment of teplizumab response using CGM |
| 42294227 | Biomarker + Multi-Omics | Liraglutide + dapagliflozin synergistically reshape gut microbiota/metabolic profile |
| 42311414 | Microbiome + Multi-Omics | Qitu qushi formula in diabetic kidney disease via gut microbiota |
| 42296503 | orforglipron + retatrutide | Benefits/harms of pharmacologic treatments in overweight/obesity (living review) |

**Key-therapy tracker** registered recent hits for all 8 tracked agents (zimislecel, orforglipron, retatrutide, CagriSema, baricitinib, teplizumab, icodec, dapagliflozin). The two **teplizumab CGM/immune-pathway papers (42269843, 42267680)** are timely given this month's FDA pediatric expansion — recommend reading both.

> Note: `domain_results` counts read as 0 in the JSON while `papers` (173) and `therapy_hits` are populated — looks like a counter not being written by `baseline_pubmed_alerts.py`. Cosmetic, but worth a one-line fix so domain volume trends are trackable. **[Likely]**

---

## Gap Analysis Summary

Top under-researched intersections (Gap Score 100 = ~zero cross-publication), **BRONZE validation — single analytic source, expert confirmation pending**:

| Rank | Intersection | Gap | Joint Pubs |
|------|-------------|-----|-----------|
| 1 | Beta Cell Regen × Health Equity | 100.0 | 0 |
| 2 | Insulin Resistance × Islet Transplant | 100.0 | 1 |
| 3 | Islet Transplant × Drug Repurposing | 100.0 | 0 |
| 4 | Islet Transplant × Health Equity | 100.0 | 0 |
| 5 | Gene Therapy × LADA | 100.0 | 0 |

**Alignment with our Tier 1 contribution areas (RESEARCH_DOCTRINE):**
- **#3 Islet Transplant × Drug Repurposing** maps directly onto **Tier 1 #4 (Drug Repurposing Computational Screening)** — we already have the islet-repurposing pipeline (`islet_repurposing_*` outputs from April). This gap is squarely in our wheelhouse and the existing analysis can be pointed at it. **Strongest actionable match.**
- **#1 / #4 Health-Equity intersections** map onto **Tier 1 #6 (Epidemiological / Health Equity Analysis)** — publicly available disparity data, low competition.
- Caveat per doctrine: these are keyword-based and may reflect terminology mismatch, not true voids. Verify each against Cochrane/PROSPERO before claiming a gap.

---

## Breaking News (web check, last ~7 days)

**Significant:**
- **Teplizumab (Tzield) — FDA pediatric expansion.** Accelerated approval (~Jun 12, 2026) to delay decline of insulin production in children **ages 8–17 with recently diagnosed Stage 3 T1D** — first FDA-approved treatment for this indication. Directly relevant to our T1D Immunotherapy domain and the active teplizumab Phase 3 trials above. ([FDA](https://www.fda.gov/news-events/press-announcements/fda-approves-new-indication-tzield-teplizumab-certain-pediatric-patients-recently-diagnosed-stage-3), [Sanofi](https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-05-05-00-3278650))
- **Orforglipron (Foundayo) — FDA approval** as a once-daily **oral** GLP-1 RA for chronic weight management (obesity / overweight + ≥1 comorbidity). One of our 8 tracked therapies. ([HCPLive](https://www.hcplive.com/view/diabetes-dialogue-orforglipron-receives-fda-approval-for-chronic-weight-management))

**Watch (no new data this week):**
- **Zimislecel (VX-880) Phase 3** still enrolling across US/Canada/Europe; Phase 1/2 NEJM data (10/12 insulin-independent at 1 yr) remains the latest read-out. Vertex regulatory submissions expected during 2026 — **flag to monitor for a filing announcement.** ([NEJM](https://www.nejm.org/doi/abs/10.1056/NEJMoa2506549), [Vertex](https://news.vrtx.com/news-releases/news-release-details/vertex-presents-positive-data-zimislecel-type-1-diabetes))

*This is a sensitive medical-research topic; items above are research/regulatory facts, not clinical advice.*

---

## Recommended Actions

1. **Update tracker + Research_Findings_Summary** with the two June FDA actions (teplizumab pediatric Stage 3; orforglipron oral GLP-1). Evidence level: regulatory/primary — treat as confirmed. *(Not done in this run — review-only per task rules.)*
2. **Re-run `project1_literature_gap_analysis.py`** with the PubMed date range extended past 2026/04/20 — `literature_gap_data.json` is 61 days stale and the report inherits that window.
3. **Read teplizumab cross-domain papers** PMID 42269843 (MS↔T1D shared pathways) and 42267680 (teplizumab response via CGM) — both relevant to the pediatric expansion.
4. **Point the existing islet-repurposing pipeline at Gap #3** (Islet Transplant × Drug Repurposing) — strongest Tier-1 alignment; verify against Cochrane/PROSPERO first.
5. **Confirm Sana Biotechnology coverage** in `baseline_clinical_trials.py` query terms — 0 Sana trials surfaced, which may be a query gap rather than reality.
6. **Minor:** fix the `domain_results` zero-count writer in `baseline_pubmed_alerts.py` so per-domain volume trends are usable.
7. **Watch:** Vertex zimislecel regulatory filing (expected 2026) — set as a standing alert.

---
*Generated by the Diabetes Hub scheduled monitor. Read-only run — no existing files were modified. Gap classifications are BRONZE (Research Doctrine v1.0) pending expert validation.*
